Scope: The following applications cover production-scale conversion of Qingban Huangbai Powder Veterinary Grade API into seven downstream dosage-form platforms. All ratios are w/w dry basis. Incoming powder is assumed to have D90 ≤ 150 µm, loss on drying ≤ 5.0%, total aerobic plate count ≤ 10⁴ CFU/g, and heavy metals ≤ 20 ppm as specified by Chinese Veterinary Pharmacopoeia 2020. Each receiving facility must revalidate these parameters against the actual certificate of analysis because seasonal harvest variability in Phellodendron amurense bark and Indigo naturalis raw materials produces batch-to-batch shifts in alkaloid content and hygroscopicity.

At API loadings above 30 wt%, direct compression becomes process-sensitive because the powder’s Carr index usually exceeds 26% once moisture rises above 4.0%. A pre-blend of Qingban Huangbai Powder, microcrystalline cellulose PH102, and crospovidone is prepared in a 30:68:2 ratio in a 600 L V-blender at 12 rpm for 18 min. Magnesium stearate at 0.5 wt% is added only in the final 3 min to avoid coating the herbal matrix and reducing tablet hardness below 1.0 MPa. Compression is run on a 45-station rotary press with 16.0 mm round flat-faced tooling at 35 rpm and a mean compression force of 14 kN. Tablet weight is maintained at 2.0 g ± 5.0% in accordance with USP <905> weight variation. Disintegration time is kept below 15 min in 0.1 M HCl at 37°C according to USP <701>. When the API fraction is increased to 40 wt%, capping appears at the band edge if residual moisture is below 2.5% or above 5.0%. The feed frame speed is then reduced to 25 rpm and pre-compression force is set to 5 kN to evacuate air. If the incoming powder has a Hausner ratio above 1.4, direct compression is replaced by roller compaction because tablet tensile strength falls below the 1.2 MPa threshold required for coated tablets. The finished tablet is a 2.0 g oral tablet containing 0.6 g Qingban Huangbai Powder, packed in HDPE bottles with 1 g silica gel desiccant.

Wet Granulation Reduces Dose-Dependent Capping in High-Load Qingban Huangbai Tablets

A 300 L high-shear granulator is charged with 40 kg Qingban Huangbai Powder, 45 kg lactose monohydrate, and 15 kg pregelatinized starch. Dry mixing runs at impeller 150 rpm and chopper 1500 rpm for 6 min. A 5% w/w povidone K30 aqueous solution is sprayed into the bowl at 35 kg/h until granulation liquid reaches 12–15% w/w of dry mass. The end point is defined by power consumption 18–22 A on the 55 kW main motor, not by time. Wet mass moisture is 12–14%. Drying is performed in a fluid-bed dryer with inlet air 60°C and product temperature held below 45°C until loss on drying is 3.0–4.0%. Dried granules are passed through a 1.0 mm oscillating mill. The granule D50 is 320–420 µm, and fines below 75 µm are kept below 20% to prevent die-fill variation. Tablets are compressed to 2.0 g with hardness 4.0–6.0 kp and friability ≤ 1.0% per USP <1216>. HPLC assay for berberine hydrochloride is performed with a C18 column, acetonitrile–0.1% phosphoric acid 45:55 mobile phase, and 265 nm detection. Granulation under these conditions causes no greater than 2.0% marker loss because product temperature does not exceed 45°C. The terminal product is a coated veterinary tablet containing 0.8 g Qingban Huangbai Powder per 2.5 g tablet, complying with dissolution Q = 75% at 45 min in 0.1 M HCl per USP <711>.

What Limits the Injectable-Grade Conversion of Qingban Huangbai Powder?

Conversion to injectable solution is constrained first by the insoluble Indigo naturalis fraction, which forms particulate matter rather than true solution. A two-stage decoction of the powder is prepared in water for injection at 95–100°C for 60 min, concentrated under vacuum at 60°C, and clarified through 0.45 µm polyethersulfone membrane. Berberine hydrochloride solubility at 20°C is approximately 2.0 g/L as the chloride salt; the free base precipitates above pH 6.0. Injection buffer is therefore adjusted to pH 4.8–5.2 with 0.1 M citrate. Bacterial endotoxin limit is set at ≤ 0.5 EU/mL for a 10 mL/kg dose administered over 1 h, calculated from K = 5 EU/kg/h in USP <85>. Terminal sterilization at 121°C for 15 min with F0 ≥ 12 causes 3.1–4.6% berberine assay loss. Formulation includes 5% overage to maintain 95.0–105.0% of label claim. Particulate matter is checked by USP <788> light obscuration method: 10 µm particles ≤ 6000 per container and 25 µm particles ≤ 600 for a 100 mL vial. Sterile filtration through 0.22 µm polyvinylidene fluoride is feasible only after activated carbon clarification; otherwise original powder particle counts exceed 10,000 per mL above 10 µm. The terminal product is a low-volume injection containing 5 mg berberine hydrochloride per 1 mL, packed in nitrogen-flushed amber glass ampoules. Published data for this specific configuration is limited beyond the general literature on Phellodendron alkaloid stability.

In capsule filling, the powder is first pre-mixed with lactose monohydrate, microcrystalline cellulose, and croscarmellose sodium in a 42.86:47.64:7.50:1.50 ratio. Magnesium stearate at 0.50% is added last. The mixture is blended in a 1000 L bin blender at 10 rpm for 20 min. Final fill weight is 0.35 g per size 0 hard gelatin capsule, delivering 0.15 g Qingban Huangbai Powder per capsule. A tamping-pin capsule filler running at 1500 capsules/min is used because the blend Hausner ratio is 1.2–1.3 and average fill is stable. Weight variation is maintained at ± 5.0% per USP <905>. Powder moisture is held below 4.0% to avoid shell embrittlement; if RH exceeds 60% in the filling suite, the powder is pre-dried at 40°C for 120 min before blending. Disintegration time remains below 15 min in water at 37°C per USP <701>. The finished product is packed in PVC/Alu blisters with 10 capsules per strip and requires no terminal sterilization because the product is administered orally.

Drinking-Water Solubility and pH-Dependent Precipitation Boundaries

Whole powder does not form a true solution in drinking water because the indigo component remains particulate. At 1.0 g/L in potable water, visible sedimentation occurs within 30 min and only 65% of dispersed solids pass a 75 µm screen after 4 h. For automatic dosing lines, a stock solution is prepared at 100 g/L by wetting the powder with 1 part ethanol, dispersing into water adjusted to pH 5.0 with 0.2% citric acid, and adding 0.1% polysorbate 80. High-shear mixing at 3000 rpm for 10 min reduces particle aggregates to a median diameter below 50 µm. Hard water above 400 ppm CaCO3 reduces dispersion stability and precipitates organic salts; a buffering system is required to hold hardness below this threshold. The final medicated water is diluted to 0.1–0.3 mg berberine hydrochloride per mL. Birds receive 10 mg/kg body weight per day in divided doses over 8 h. The solution is consumed within 12 h to prevent microbial growth; total aerobic plate count remains below 100 CFU/mL for 24 h only when stored at ≤ 8°C. The terminal product is a 500 g soluble powder pouch, added to 1000 L drinking water per administration.

In feed premises containing 200 mg Qingban Huangbai Powder per kg complete feed, a 10% API premix is prepared with 88.5% calcium carbonate carrier, 1.0% precipitated silica, and 0.5% mineral oil. Mixing is performed in a 2-ton horizontal ribbon mixer at 20 rpm for 20 min. Blend uniformity is tested on 10 sampling points with coefficient of variation ≤ 5.0% according to ASTM E2810-19. If incoming API has D90 above 250 µm, the uniformity coefficient rises above 7.0%, so the powder is pre-milled to D90 ≤ 150 µm using a pin mill. Pelleting of feed containing this premix is performed at conditioner temperature 70°C for 45 s; berberine assay loss under these conditions is ≤ 6.0%. If the feed mill employs higher conditioning temperatures, a post-pelleting liquid spray is substituted to avoid thermal degradation of the heat-sensitive alkaloids. The terminal premix is packed in 25 kg paper bags with PE liner and added at 2 kg per ton complete feed.

When Fluid-Bed Granulation Is Substituted for Roller Compaction in Granule Production

Roller compaction at 30 kN/cm pressure and dry milling through a 1.5 mm screen yields granules with Hausner ratio 1.2, but fines below 75 µm are typically 18–22%. When fines exceed 25%, filling volume drift is observed in stick-pack lines. The process is then switched to fluid-bed top-spray granulation. A 10% maltodextrin and 5% sucrose binder solution in water at 50°C is sprayed at 80 g/min in a Glatt GPCG 120 with inlet air 65°C, product temperature 38°C, and atomizing air 2.5 bar. Final granule D50 is 280 µm and loss on drying is 2.5–3.5%. Sieving through 16–40 mesh removes oversize and fines. The granule product contains 250 mg Qingban Huangbai Powder per 1.0 g sachet. Dissolution in warm water at 40°C produces a uniform suspension with no floating aggregates. Terminal packaging is aluminum-laminated stick-packs under ≤ 3.0% oxygen headspace.

For herd water medication where the premix cannot be used, a 20% w/v oral suspension is prepared in deionized water containing 0.15% xanthan gum, 0.1% sodium citrate, 0.05% potassium sorbate, and 10% propylene glycol. High-shear mixing at 5000 rpm for 15 min is followed by a colloid mill pass with gap set to 0.3 mm. Viscosity is 1200–1800 cP at 25°C with Brookfield LV, spindle 3, 60 rpm; pH is maintained at 5.0–5.5. Each milliliter delivers 0.2 g Qingban Huangbai Powder via a 5 mL oral dosing syringe. Suspension uniformity is measured top/middle/bottom after 30 days at 25°C/60% RH; assay variance is ≤ 5.0%. Microbial limits of total aerobic count ≤ 10³ CFU/g and yeast/mold ≤ 10² CFU/g are controlled by the preservative system, not by terminal sterilization. The product is packed in 100 mL amber PET bottles with child-resistant closures.